scholarly journals Methylation alteration of SHANK1 as a predictive, diagnostic and prognostic biomarker for chronic lymphocytic leukemia

Oncotarget ◽  
2019 ◽  
Vol 10 (48) ◽  
pp. 4987-5002 ◽  
Author(s):  
Eleonora Loi ◽  
Loredana Moi ◽  
Antonio Fadda ◽  
Giannina Satta ◽  
Mariagrazia Zucca ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Prognostic Biomarker ◽  
Lymphocytic Leukemia ◽  
Methylation Alteration

A novel, mitochondrial, internal tRNA-derived RNA fragment possesses clinical utility as a molecular prognostic biomarker in chronic lymphocytic leukemia

2020 ◽  
Vol 85 ◽  
pp. 20-26
Author(s):  
Paraskevi Karousi ◽  
Panagiotis G. Adamopoulos ◽  
Sotirios G. Papageorgiou ◽  
Vasiliki Pappa ◽  
Andreas Scorilas ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Clinical Utility ◽  
Prognostic Biomarker ◽  
Lymphocytic Leukemia

scholarly journals CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression

Blood ◽  
2020 ◽  
Vol 135 (15) ◽  
pp. 1244-1254 ◽  
Author(s):  
Erika Tissino ◽  
Federico Pozzo ◽  
Dania Benedetti ◽  
Chiara Caldana ◽  
Tamara Bittolo ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Disease Progression ◽  
Prognostic Biomarker ◽  
Lymphocytic Leukemia ◽  
Prognostic Impact ◽  
Clinical Behavior ◽  
Cutoff Value ◽  
Sequential Samples ◽  
Homogeneous Pattern ◽  
Over Time

Abstract CD49d is a remarkable prognostic biomarker of chronic lymphocytic leukemia (CLL). The cutoff value for the extensively validated 30% of positive CLL cells is able to separate CLL patients into 2 subgroups with different prognoses, but it does not consider the pattern of CD49d expression. In the present study, we analyzed a cohort of 1630 CLL samples and identified the presence of ∼20% of CLL cases (n = 313) characterized by a bimodal expression of CD49d, that is, concomitant presence of a CD49d+ subpopulation and a CD49d− subpopulation. At variance with the highly stable CD49d expression observed in CLL patients with a homogeneous pattern of CD49d expression, CD49d bimodal CLL showed a higher level of variability in sequential samples, and an increase in the CD49d+ subpopulation over time after therapy. The CD49d+ subpopulation from CD49d bimodal CLL displayed higher levels of proliferation compared with the CD49d− cells; and was more highly represented in the bone marrow compared with peripheral blood (PB), and in PB CLL subsets expressing the CXCR4dim/CD5bright phenotype, known to be enriched in proliferative cells. From a clinical standpoint, CLL patients with CD49d bimodal expression, regardless of whether the CD49d+ subpopulation exceeded the 30% cutoff or not, experienced clinical behavior similar to CD49d+ CLL, both in chemoimmunotherapy (n = 1522) and in ibrutinib (n = 158) settings. Altogether, these results suggest that CD49d can drive disease progression in CLL, and that the pattern of CD49d expression should also be considered to improve the prognostic impact of this biomarker in CLL.

Soluble CD163 as a prognostic biomarker in B-cell chronic lymphocytic leukemia

2015 ◽  
Vol 56 (11) ◽  
pp. 3219-3221 ◽  
Author(s):  
Line Nederby ◽  
Anne S. Roug ◽  
Signe S. Knudsen ◽  
Anni Skovbo ◽  
Eigil Kjeldsen ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
B Cell ◽  
Prognostic Biomarker ◽  
Lymphocytic Leukemia ◽  
Soluble Cd163 ◽  
Cell Chronic Lymphocytic Leukemia
Sign in / Sign up

Export Citation Format

Share Document